4
|
Sousa H, Mesquita L, Ribeiro J, Catarino R, Breda E, Medeiros R. Polymorphisms in host immune response associated genes and risk of nasopharyngeal carcinoma development in Portugal. Immunobiology 2016; 221:145-52. [PMID: 26391153 DOI: 10.1016/j.imbio.2015.09.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Revised: 08/21/2015] [Accepted: 09/08/2015] [Indexed: 12/12/2022]
Abstract
BACKGROUND Host genetic susceptibility markers in immune response associated genes may contribute to identify individuals with high risk of developing viral infection and viral-associated cancers. We aimed to characterize different polymorphisms in immune response associated genes and evaluate its association with nasopharyngeal carcinoma (NPC) development. METHODS We have developed a hospital-based case-control study selecting 134 patients with NPC (cases) and 732 healthy individuals (controls) from the Northern Region of Portugal. Eight single nucleotide polymorphisms (SNP) were selected: -56C>T IFNGR1 (rs2234711), +4854G>T IL1A (rs17561), +3954C>T IL1B (rs1143634), +1902A>G IL4RA (rs1801275), -1082G>A IL10 (rs1800896), +2018T>C IL1RN (rs419598), HLA-A locus A>T (rs2530388), HCGA9 locus A>T (rs6457110). All polymorphisms were analysed by real-time methodology using TaqMan(®) SNP Genotyping Assays. RESULTS The overall analysis revealed no statistical significant differences between genotypes distributions in all of studied polymorphisms (p>0.05). However, the results for HCGA9 rs6457110 polymorphism showed a tendency for an increased risk of NPC development among TT carriers with an almost of 2-fold increased risk (OR=1.86; 95%CI 1.00-3.65). CONCLUSIONS This is the first study to characterize these polymorphisms in NPC patients in Portugal. Our study indicates that HCGA9 rs6457110 polymorphism might represent a risk marker for NPC development in our population and that other SNPs should be further studied in larger populations to clarify the evidences. This data reinforces the need for more studies, especially in NPC low-prevalent populations.
Collapse
Affiliation(s)
- Hugo Sousa
- Molecular Oncology & Viral Pathology Group (CI-IPOP), Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal; Virology Service, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal.
| | - Letícia Mesquita
- Molecular Oncology & Viral Pathology Group (CI-IPOP), Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal
| | - Joana Ribeiro
- Molecular Oncology & Viral Pathology Group (CI-IPOP), Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal; Virology Service, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal; Research Department, Portuguese League against Cancer (Liga Portuguesa Contra o Cancro - Núcleo Regional do Norte), Porto, Portugal
| | - Raquel Catarino
- Molecular Oncology & Viral Pathology Group (CI-IPOP), Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal
| | - Eduardo Breda
- Molecular Oncology & Viral Pathology Group (CI-IPOP), Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal; Otorhinolaryngology Service, Portuguese Institute of Oncology of Porto Porto FG EPE, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal
| | - Rui Medeiros
- Molecular Oncology & Viral Pathology Group (CI-IPOP), Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal; Virology Service, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal; Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal; Research Department, Portuguese League against Cancer (Liga Portuguesa Contra o Cancro - Núcleo Regional do Norte), Porto, Portugal
| |
Collapse
|
5
|
Fonseka TM, Müller DJ, Kennedy SH. Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. MOLECULAR NEUROPSYCHIATRY 2016; 2:1-14. [PMID: 27606316 DOI: 10.1159/000441521] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Accepted: 10/06/2015] [Indexed: 01/07/2023]
Abstract
Antipsychotic medications (APs), particularly second-generation APs, are associated with significant weight gain in schizophrenia patients. Recent evidence suggests that the immune system may contribute to antipsychotic-induced weight gain (AIWG) via AP-mediated alterations of cytokine levels. Antipsychotics with a high propensity for weight gain, such as clozapine and olanzapine, influence the expression of immune genes, and induce changes in serum cytokine levels to ultimately down-regulate neuroinflammation. Since inflammatory cytokines are normally involved in anorexigenic responses, reduced inflammation has been independently shown to mediate changes in feeding behaviours and other metabolic parameters, resulting in obesity. Genetic variation in pro-inflammatory cytokines is also associated with both general obesity and weight change during AP treatment, and thus, may be implicated in the pharmacogenetics of AIWG. At this time, preliminary data support a cytokine-mediated model of AIWG which may have clinical utility in developing more effective metabolic monitoring guidelines and prevention measures. However, further research is still needed to clearly elucidate the validity of this immune model. This article reviews the evidence implicating inflammatory cytokines in AIWG and its potential clinical relevance.
Collapse
Affiliation(s)
- Trehani M Fonseka
- Department of Psychiatry, University Health Network, University of Toronto, Toronto, Ont., Canada; Department of Psychiatry, St. Michael's Hospital, University of Toronto, Toronto, Ont., Canada; Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ont., Canada
| | - Daniel J Müller
- Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ont., Canada
| | - Sidney H Kennedy
- Department of Psychiatry, University Health Network, University of Toronto, Toronto, Ont., Canada; Department of Psychiatry, St. Michael's Hospital, University of Toronto, Toronto, Ont., Canada
| |
Collapse
|
6
|
Herder C, Nuotio ML, Shah S, Blankenberg S, Brunner EJ, Carstensen M, Gieger C, Grallert H, Jula A, Kähönen M, Kettunen J, Kivimäki M, Koenig W, Kristiansson K, Langenberg C, Lehtimäki T, Luotola K, Marzi C, Müller C, Peters A, Prokisch H, Raitakari O, Rathmann W, Roden M, Salmi M, Schramm K, Swerdlow D, Tabak AG, Thorand B, Wareham N, Wild PS, Zeller T, Hingorani AD, Witte DR, Kumari M, Perola M, Salomaa V. Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits. Diabetes 2014; 63:4343-59. [PMID: 24969107 PMCID: PMC4237993 DOI: 10.2337/db14-0731] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The proinflammatory cytokine interleukin (IL)-1β is implicated in the development of insulin resistance and β-cell dysfunction, whereas higher circulating levels of IL-1 receptor antagonist (IL-1RA), an endogenous inhibitor of IL-1β, has been suggested to improve glycemia and β-cell function in patients with type 2 diabetes. To elucidate the protective role of IL-1RA, this study aimed to identify genetic determinants of circulating IL-1RA concentration and to investigate their associations with immunological and metabolic variables related to cardiometabolic risk. In the analysis of seven discovery and four replication cohort studies, two single nucleotide polymorphisms (SNPs) were independently associated with circulating IL-1RA concentration (rs4251961 at the IL1RN locus [n = 13,955, P = 2.76 × 10(-21)] and rs6759676, closest gene locus IL1F10 [n = 13,994, P = 1.73 × 10(-17)]). The proportion of the variance in IL-1RA explained by both SNPs combined was 2.0%. IL-1RA-raising alleles of both SNPs were associated with lower circulating C-reactive protein concentration. The IL-1RA-raising allele of rs6759676 was also associated with lower fasting insulin levels and lower HOMA insulin resistance. In conclusion, we show that circulating IL-1RA levels are predicted by two independent SNPs at the IL1RN and IL1F10 loci and that genetically raised IL-1RA may be protective against the development of insulin resistance.
Collapse
Affiliation(s)
- Christian Herder
- Institute of Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany German Center for Diabetes Research (DZD e.V.), partner site Düsseldorf, Germany
| | - Marja-Liisa Nuotio
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland Unit of Public Health Genomics, National Institute for Health and Welfare, Helsinki, Finland
| | - Sonia Shah
- Centre of Neurogenetics and Statistical Genomics, Queensland Brain Institute, University of Queensland, St. Lucia, QLD, Australia
| | - Stefan Blankenberg
- Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg, Lübeck, Kiel, Germany
| | - Eric J Brunner
- Department of Epidemiology and Public Health, University College London, London, U.K
| | - Maren Carstensen
- Institute of Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany German Center for Diabetes Research (DZD e.V.), partner site Düsseldorf, Germany
| | - Christian Gieger
- Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Harald Grallert
- Research Unit Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany German Center for Diabetes Research (DZD e.V.), partner site, Munich, Germany
| | - Antti Jula
- National Institute for Health and Welfare, Turku, Finland
| | - Mika Kähönen
- Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Johannes Kettunen
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland Unit of Public Health Genomics, National Institute for Health and Welfare, Helsinki, Finland Computational Medicine, Institute of Health Sciences, University of Oulu and Oulu University Hospital, Oulu, Finland
| | - Mika Kivimäki
- Department of Epidemiology and Public Health, University College London, London, U.K
| | - Wolfgang Koenig
- Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
| | - Kati Kristiansson
- Unit of Public Health Genomics, National Institute for Health and Welfare, Helsinki, Finland
| | - Claudia Langenberg
- Department of Epidemiology and Public Health, University College London, London, U.K. MRC Epidemiology Unit, Cambridge University, Cambridge, U.K
| | - Terho Lehtimäki
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland
| | - Kari Luotola
- Department of Obstetrics and Gynecology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
| | - Carola Marzi
- Research Unit Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany German Center for Diabetes Research (DZD e.V.), partner site, Munich, Germany
| | - Christian Müller
- Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg, Lübeck, Kiel, Germany
| | - Annette Peters
- Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany German Center for Diabetes Research (DZD e.V.), partner site, Munich, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Munich, Germany
| | - Holger Prokisch
- Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany Institute of Human Genetics, Technical University Munich, Munich, Germany
| | - Olli Raitakari
- Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
| | - Wolfgang Rathmann
- Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Michael Roden
- Institute of Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany German Center for Diabetes Research (DZD e.V.), partner site Düsseldorf, Germany Department of Endocrinology and Diabetology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany
| | - Marko Salmi
- National Institute for Health and Welfare, Turku, Finland MediCity Research Laboratory, University of Turku, Turku, Finland Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland
| | - Katharina Schramm
- Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany Institute of Human Genetics, Technical University Munich, Munich, Germany
| | - Daniel Swerdlow
- Institute of Cardiovascular Sciences, University College London, London, U.K
| | - Adam G Tabak
- Department of Epidemiology and Public Health, University College London, London, U.K. 1st Department of Medicine, Semmelweis University Faculty of Medicine, Budapest, Hungary
| | - Barbara Thorand
- Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Nick Wareham
- MRC Epidemiology Unit, Cambridge University, Cambridge, U.K
| | - Philipp S Wild
- Department of Medicine 2, University Medical Center Mainz, Mainz, Germany Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Rhine-Main, Mainz, Germany
| | - Tanja Zeller
- Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg, Lübeck, Kiel, Germany
| | - Aroon D Hingorani
- Institute of Cardiovascular Sciences, University College London, London, U.K
| | - Daniel R Witte
- Centre de Recherche Public de la Santé, Strassen, Luxembourg
| | - Meena Kumari
- Department of Epidemiology and Public Health, University College London, London, U.K
| | - Markus Perola
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland Unit of Public Health Genomics, National Institute for Health and Welfare, Helsinki, Finland Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - Veikko Salomaa
- Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
| |
Collapse
|
9
|
Andersson N, Strandberg L, Nilsson S, Adamovic S, Karlsson MK, Ljunggren O, Mellström D, Lane NE, Zmuda JM, Nielsen C, Orwoll E, Lorentzon M, Ohlsson C, Jansson JO. A variant near the interleukin-6 gene is associated with fat mass in Caucasian men. Int J Obes (Lond) 2010; 34:1011-9. [PMID: 20157327 PMCID: PMC2885503 DOI: 10.1038/ijo.2010.27] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Context Regulation of fat mass appears to be associated with immune functions. Studies of knockout mice show that endogenous interleukin (IL)-6 can suppress mature-onset obesity. Objective To systematically investigate associations of single nucleotide polymorphisms (SNPs) near the IL-6 (IL6) and IL-6 receptor (IL6R) genes with body fat mass, in support for our hypothesis that variants of these genes can be associated with obesity. Design and Study Subjects The Gothenburg Osteoporosis and Obesity Determinants (GOOD) study is a population-based cross-sectional study of 18-20 years old men (n=1 049), from the Gothenburg area (Sweden). Major findings were confirmed in two additional cohorts consisting of elderly men from the Osteoporotic Fractures in Men (MrOS) Sweden (n=2 851) and MrOS US (n=5 611) multicenter population-based studies. Main Outcome The genotype distributions and their association with fat mass in different compartments, measured with dual-energy X-ray absorptiometry (DXA). Results Out of 18 evaluated tag single nucleotide polymorphisms (SNPs) near the IL6 and IL6R genes, a recently identified SNP rs10242595 G/A [minor allele frequency (MAF) = 29%] 3′ of the IL6 gene was negatively associated with the primary outcome total body fat mass (effect size -0.11 standard deviation (SD) units/A allele, P=0.02). This negative association with fat mass was also confirmed in the combined MrOS Sweden and MrOS US cohorts (effect size -0.05 SD units/A allele; P=0.002). When all three cohorts were combined (n= 8 927, Caucasian subjects), rs10242595*A showed a negative association with total body fat mass (effect size -0.05 SD units/A allele, P<0.0002). Furthermore, the rs10242595*A was associated with low body mass index [(BMI, effect size -0.03, P<0.001)] and smaller regional fat masses. None of the other SNPs investigated in the GOOD study were reproducibly associated with body fat. Conclusions The IL6 gene polymorphism rs10242595*A is associated with decreased fat mass in three combined cohorts of 8 927 Caucasian men.
Collapse
Affiliation(s)
- N Andersson
- Department of Physiology/Endocrinology, Sahlgrenska Academy, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|